Document Detail


Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
MedLine Citation:
PMID:  2340463     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia. The authors' goal was to treat patients with continuous infusion mitoxantrone in order to maintain cytotoxic steady state levels with acceptable toxicity and to assess the results. Daily mitoxantrone levels showed a mean steady state plasma level of 16.8 +/- 1.4 ng/ml (range, 9.1-25.1) with a systemic clearance of 519 +/- 47 ml/minute/m2. No drug accumulation occurred. Mitoxantrone was undetectable 24 hours postinfusion. All patients, including two patients with chronic myelogenous leukemia in blast phase, had greater than 90% reduction in leukemia cell mass (marrow cellularity X percent leukemia cells) by day 6. However, six patients received 3 days of etoposide at that point because of residual acute nonlymphocytic leukemia (ANLL). Overall four patients (36%) had a complete remission; one additional patient had a bone marrow remission but also had a persistent granulocytic sarcoma. Toxicities included severe but tolerable myelosuppression, mucositis, and hepatic dysfunction. There was no correlation between mitoxantrone levels, toxicity, or clinical response. Continuous infusion produces cytotoxic plasma mitoxantrone levels and rapid clearing of ANLL from bone marrow. Further dose escalation may be possible.
Authors:
L S Kaminer; K E Choi; K M Daley; R A Larson
Related Documents :
2647183 - Recipients of hla-identical sibling marrow transplants with severe aplastic anemia engr...
12931223 - Is fish a relevant prognostic tool in myelodysplastic syndromes with a normal chromosom...
3471273 - Serum ca 125 in epithelial ovarian cancer. a longitudinal study.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer     Volume:  65     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1990 Jun 
Date Detail:
Created Date:  1990-06-28     Completed Date:  1990-06-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2619-23     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, University of Chicago, Illinois.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Bone Marrow / pathology
Etoposide / therapeutic use
Female
Humans
Infusions, Intravenous
Leukemia, Myeloid, Acute / blood,  drug therapy*,  pathology
Male
Middle Aged
Mitoxantrone / administration & dosage,  blood,  pharmacokinetics,  therapeutic use*,  toxicity
Neoplasm Recurrence, Local*
Remission Induction
Grant Support
ID/Acronym/Agency:
CA-28734/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
33419-42-0/Etoposide; 65271-80-9/Mitoxantrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leuke...
Next Document:  High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic l...